$5.12
-1.9%CalciMedica, Inc., a clinical-stage biotechnology company, focuses on developing therapies for life-threatening inflammatory diseases with unmet needs. Its proprietary technology targets the inhibition of calcium release-activated (CRAC) channels designs to modulate the immune response and protect against tissue cell injury in life-threatening inflammatory diseases. Its lead product candidate is Auxora, a proprietary intravenous-formulated CRAC channel inhibitor for the treatment of acute pancreatitis, asparaginase-associated acute pancreatitis, and acute kidney injury. The company is based in La Jolla, California.
Chief Business Officer & Vice Chairman of the Board
Compensation
$390,600
Chief Executive Officer & Director
Compensation
$416,944
Chief Financial Officer
Chief Medical Officer
Compensation
$424,904
Co-Founder & Chief Scientific Officer
Compensation
$615,594
Co-Founder and Scientific Advisor
Co-Founder and Scientific Advisor
Co-Founder and Scientific Advisor
General Counsel
President & Chief Operating Officer
During the last 12 months, insiders have purchased $249K and sold $4K worth of CALC shares, resulting in $246K of net buying activity.
0
0.00
0
0.00
+0
+$0
0
0.00
0
0.00
+0
+$0
13.2K
39.76K
0
0.00
+40K
+$40K
85.2K
209.48K
1.0K
3.65K
+206K
+$206K
Roberts Eric W
Director, 10 Percent Owner, Officer: Chief Business Officer
$175K
Hebbar Sudarshan
Officer: Chief Medical Officer
$43K
Wilson Robert N
Director
$13K
Leheny A. Rachel
Director, 10 Percent Owner, Officer: Chief Executive Officer
$10K
Stauderman Kenneth A.
Officer: Chief Scientific Officer
$6K
Stauderman Kenneth A.
Officer: Chief Scientific Officer
$4K
Strong bullish signal with $246K net buying. Insiders are aggressively accumulating shares, suggesting significant confidence in future prospects.
Exceptional buy/sell ratio. Buying dramatically outweighs selling—one of the strongest possible insider signals.
5 insider buyers vs. 1 sellers. Broad-based buying across management team suggests widespread confidence.
Compelling insider conviction: The combination of strong buy/sell ratio and multiple buyers suggests insiders see attractive risk/reward. Consider this alongside fundamental analysis for confirmation.
CALC - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2025 N/A | April 29, 2025 | June 24, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | July 16, 2024 | August 27, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | June 28, 2023 | August 09, 2023 | 2023 | |
DEF 14A DEF 14A 2022 N/A | April 22, 2022 | June 02, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | April 23, 2021 | June 02, 2021 | 2021 |
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.